CPE Leads USD224m Investment in Chinese Cancer Diagnostics Company 3DMed Diagnostic

Source(s): DealStreetAsia

CITIC’s alternative asset manager CPE led a CNY1.5b (approximately USD224m) investment in 3DMed Diagnostic, a China-based cancer diagnostics company spun out of 3D Medicines, with participation from CICC Capital, Jemincare, Tsing Song Capital, Spinnotec, Haier Biomedical, Ruiyi Investment, and LanShang Capital. Read more